On Jan. 04, Auerbach Alan H divested U.S. $186,380 in shares of Puma Biotechnology Inc.. The Pres, CEO, 10% sold 18,235 shares at a price per share of $10.22. The transaction decreased this specific insider’s holdings to 4,284,258 shares worth around $45.67 million at present.
Meanwhile, Goldman had lowered its rating on PBYI to “Sell” from the earlier “Neutral”, in a research note produced for clients October 08, 2019. In addition, there was a downgrade from Citigroup on May 10, 2019. The rater changed PBYI from “a Buy” to “a Neutral”.
Is Puma Biotechnology Inc. [NASDAQ:PBYI] a Good Buy Right Now?
It should be noted that PBYI technical indicators for short, intermediate as well as long term progress have placed an overall average of 64% as Buy. The average signal changed from 32% Buy in the last week and compares with 40% Buy in the past month. Data from Puma Biotechnology Inc.’s Trend Spotter indicated that the signals were Bullish. The stock current average is 0.6 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.57 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 50% Buy and the 100-day average volume stands at 0.59 million shares.
PBYI Price Performance
On Wall Street, Puma Biotechnology Inc. [NASDAQ:PBYI] finished Wednesday’s session up 0.09% at $10.66. The stock went up to $11.05 at the same session while its lowest single day price was $10.45. In the last five days, it saw a rise of about 5.23%, Puma Biotechnology Inc. shares gained by almost 3.90% since the beginning of the year. However, the share price has dropped to as low as -28.93% below its one year high. On 01/06/21, the company shares recorded $11.05, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $10.16. The company’s shares have inclined by 29.84% in the past year. The 50-day SMA achieved is $10.24 while the 200-day SMA is $10.18. Volume dropped to 0.3 million from 0.37 million in the previous session.
Puma Biotechnology Inc. [PBYI] Valuation Measures
Notably, Puma Biotechnology Inc. [PBYI] stock can be helpful for investors to consider historical price-sales ratio, more specifically, a 1.82 PS value ratio is reported for the last one year of reported earnings. That is lower than the industry average of 20.33.
PBYI Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 10.39 level, and in case of violation of this particular level, it will cause more drop to 10.12 level. On the upper level, 11.32 is still the key resistance. The stock may increase to the subsequent resistance at 10.99. The Relative Strength Index (RSI) pinned on the 14-day chart is 48.99, implying a neutral technical stance while the MACD stands at -0.36, meaning price will decrease in the next trading period. Percent R indicator moved to 71.89%, implying bearish price movement. Stochastic %K at 22.89% suggest holding the stock.
What is the short interest in Puma Biotechnology Inc.?
Short interest in the Puma Biotechnology Inc. stock has surged, increasing by 0.27 million shares to total 7.81 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 8.08 million, data from Yahoo Finance shows. The decrease of -3.46% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 25.55% of the overall float for the stock.
Puma Biotechnology Inc.’s Biggest Shareholders: Who Owns Puma Biotechnology Inc. [PBYI]?
Filings by The Vanguard Group, Inc. showed that the firm now holds a total of 3,379,485 shares or roughly 8.50% of the outstanding PBYI shares. This means their shares have reduced by -851,894 from the 3,379,485 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Fred Alger Management LLC updated stake is worth $37,490,884. The Camber Capital Management LP’s holdings currently number 2,555,000 shares at $27236300.0. According to the firm’s last 13F report, BlackRock Fund Advisors shares in the company at filing stood at 2,506,218 shares, roughly $28,194,953.
PBYI Earnings Forecast For The Current Quarter
Puma Biotechnology Inc. [PBYI] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $55.67M and an earnings per share of -$0.28 for Dec 2020. Looking further ahead, the company is expected to report revenue of $57.31M at an EPS of -$0.48 for Mar 2021. The estimates represent downside of 6.30% and 20.30% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
PBYI Earnings Estimates For The Current Year
For the financial year, Puma Biotechnology Inc. [NASDAQ:PBYI] is expected to bring in revenue of $225.96M. The returns are nearly $-46.34 million lower than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.28, higher than that of FY19 by $0.67. Estimates put this year’s earnings growth at 34.40%, 20.30% for the next, and at an annual 232.50% over the next 5-year period. As for sales, forecasts are for a decrease of -17.00% in the current fiscal year and a further 6.30% over the following year.
What are analyst thoughts on Puma Biotechnology Inc.?
Looking forward to the Puma Biotechnology Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Puma Biotechnology Inc. stock at $9.00 within the next 12 months, which represents almost -18.44 per cent growth from its previous closing price of $10.66. The highest analysts’ target for Puma Biotechnology Inc. stock projections is $15.00 and the lowest one is $6.00. Still, 8 analysts sharing their consensus rating for PBYI stock in 2021 agree that it is an Underweight.